Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
immuncell-lc + sorafenib
- Development stage
- Phase 2
- Lead developer
- GC Cell
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Immuncell-LC + sorafenib is an investigational combination therapy made up of *Immuncell-LC*, a natural killer (NK) cell-based autologous cell immunotherapy, and *sorafenib*, a small molecule multitargeted kinase inhibitor approved for hepatocellular carcinoma and other indications. Immuncell-LC is designed to augment the body’s immune response, primarily through activation of cytotoxic T lymphocytes and NK cells, enhancing antitumor immunity. Sorafenib targets multiple kinases involved in tumor cell proliferation and angiogenesis, including VEGFR and RAF kinases. The combination aims to synergize immune activation and targeted inhibition of tumor growth and vasculature to enhance anticancer effects while minimizing toxicity. This strategy is being investigated for advanced hepatocellular carcinoma, leveraging Immuncell-LC’s immune modulation to overcome the immunosuppressive tumor microenvironment that can limit sorafenib efficacy[1].
- Brand names
- nexavar
- Other names
- immuncell-lcsorafenibnexavar
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FLT3 (Fms related receptor tyrosine kinase 3)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on immuncell-lc + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on immuncell-lc + sorafenib.